PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 8, 2026PLoS ONE0 citationsOpen Access

Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration

View Full Paper
JIJohannes IbyMedical University of ViennaLCLeonard CoulibalyMedical University of ViennaMHMarlene HollausMedical University of Vienna

Key Points

  • The study aims to evaluate the efficacy of switching from aflibercept to ranibizumab in treating neovascular age-related macular degeneration.
  • Compared visual outcomes after switching treatments
  • Analyzed the impact of age and previous injections
  • Measured changes in central macular thickness (CMT)
  • Switching to ranibizumab resulted in non-inferior visual outcomes
  • Age and previous injections influenced CMT changes
  • Findings support the potential for optimizing treatment strategies through drug switching

Abstract

Our study indicates that changes in CMT are affected by age, the number of previous injections, and the time interval between visits. These biomarkers may offer valuable insights for future research on switching anti-VEGF drugs to optimize treatment strategies for nAMD. A single dose treatment switch to ranibizumab yielded non-inferior outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Iby et al. (2026) studied this question.

synapsesocial.com/papers/69ada8dfbc08abd80d5bc508https://doi.org/10.1371/journal.pone.0342927
Ask AI
Helpful
Bookmark
Share
View Full Paper